This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot (ISEOD)

This study has been terminated.
(The study has proven to be infeasible.)
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes Identifier:
First received: March 23, 2011
Last updated: March 24, 2015
Last verified: March 2015
The investigators' primary objective is to assess the predictive power of PET/CT scanning in the evolution of infectious osteoarthritis of the diabetic diabetic after antibiotic therapy prescribed by national and international recommendations.

Condition Intervention
Diabetic Foot Osteoarthritis Procedure: Bone scintigraphy Procedure: Leukoscan Procedure: PET / CT Procedure: Bone biopsy Biological: Bloodwork

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Positron Emission Tomography - Computed Tomography (PET/CT) Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nīmes:

Primary Outcome Measures:
  • The difference between AUCs for PET/CT scan and scintigraphy [ Time Frame: 1 year ]

Enrollment: 12
Study Start Date: October 2012
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Included patients

Patients included in the study according to stated inclusion and exclusion criteria

Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork

Procedure: Bone scintigraphy
Bone scintigraphy of the affected area
Procedure: Leukoscan
Scintigraphy with labeled neutrophils
Procedure: PET / CT
PET / CT of the affected area
Procedure: Bone biopsy
A bone biopsy is performed during pre-inclusion work up.
Biological: Bloodwork
CRP and procalcitonin are measured in the pre-inclusion work up.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • Patient has type I or type II diabetes
  • Patient consulting in the department of Metabolic and Endocrine Diseases (Caremeau Hospital) or the department of Nutritional Diseases and Diabetology (Grau de Roi Medical Center) at the Nîmes University Hospital
  • Patient has infected osteoarthritis of the foot according to the International Working Group on the Diabetic Foot with a probability > 50% (score >= 2).

Exclusion Criteria:

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant
  • The patient is breastfeeding
  • Patient has severe sepsis or a stage 4 infection according to the international consensus on the diabetic foot
  • Patient has severe renal insufficiency as defined by glomerular filtration rate < 30ml/min/1.73 m^2, calculated according to the MDRD equation, and is not undergoing dialysis
  • Patient has a contra-indication for an MRI
  • pacemaker
  • intracranial clips
  • metallic inclusions
  • severe claustrophobia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01322256

Centre Hospitalier Universitaire de Nîmes
Nîmes Cedex 09, Gard, France, 30029
CHU de Nîmes - Hôpital Universitaire de Réadaptation du Grau du Roi
Le Grau du Roi, France, 30240
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Study Director: Sophie Schuldiner, MD Centre Hospitalier Universitaire de Nîmes
Principal Investigator: Nathalie Jourdan, MD Centre Hospitalier Universitaire de Nîmes
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nīmes Identifier: NCT01322256     History of Changes
Other Study ID Numbers: AOI/2009/SJ-01
2010-020160-38 ( Other Identifier: RCB number )
Study First Received: March 23, 2011
Last Updated: March 24, 2015

Additional relevant MeSH terms:
Diabetic Foot
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Foot Ulcer
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017